Marinus Pharmaceuticals (MRNS) PT Raised to $0.55 at Baird Dec 30, 2024 11:39PM
Marinus Pharma (MRNS) Acquired by Immedica for $0.55/sh Dec 30, 2024 07:00AM
Marinus Pharma (MRNS) Misses Q3 EPS by 1c, narrows product revenue guidance Nov 12, 2024 04:01PM
Jefferies Downgrades Marinus Pharmaceuticals (MRNS) to Hold Oct 24, 2024 04:34PM
Marinus Pharmaceuticals (MRNS) PT Lowered to $0.50 at Baird Oct 24, 2024 01:59PM


Oct 24, 2024 11:06AM Truist Securities Downgrades Marinus Pharmaceuticals (MRNS) to Hold
Oct 24, 2024 08:01AM Marinus Pharma (MRNS) Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Did Not Meet Primary Endpoint
Oct 24, 2024 07:55AM Marinus Pharma (MRNS) Halted, News Pending
Oct 17, 2024 07:00AM Marinus Pharma (MRNS) Presents Clinical Data From Pivotal Phase 3 RAISE Trial
Oct 15, 2024 04:01PM Marinus Pharma (MRNS) Receives Method of Treatment Patent for ZTALMY Titration Regimens
Sep 23, 2024 07:39AM TD Cowen Reiterates Buy Rating on Marinus Pharmaceuticals (MRNS)
Sep 23, 2024 03:08AM Oppenheimer Upgrades Marinus Pharmaceuticals (MRNS) to Outperform
Sep 20, 2024 08:03AM Marinus Pharma (MRNS) to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY in TSC at Investor and Analyst Day
Aug 14, 2024 02:17PM TD Cowen Reiterates Buy Rating on Marinus Pharmaceuticals (MRNS)
Aug 13, 2024 04:09PM JMP Securities Reiterates Market Outperform Rating on Marinus Pharmaceuticals (MRNS)
Aug 13, 2024 04:04PM Truist Securities Reiterates Buy Rating on Marinus Pharmaceuticals (MRNS)
Aug 13, 2024 07:05AM Marinus Pharma (MRNS) Misses Q2 EPS by 4c ; Offers Guidance
Jul 18, 2024 07:01AM Marinus Pharma (MRNS) Announces Ganaxolone Approved in China
Jun 17, 2024 07:00AM Marinus Pharma (MRNS) Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus